

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re *Inter Partes* Reexamination of U.S. Patent No. 8,057,825

Entitled: Krill Extracts for Treatment of Cardiovascular Diseases

Issued: 15 November 2011 to Sampalis

**DECLARATION BY DR. NILS HOEM IN SUPPORT OF  
REQUEST FOR INTER PARTES REEXAMINATION OF  
U.S. PATENT NO. 8,057,825**

**EFS WEB Filed**

Mail Stop Inter Partes Reexam  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I, Dr. Nils Hoem, state as follows:

1. My present position is Chief Scientist of Aker Biomarine ASA. My Curriculum Vitae is attached hereto as Exhibit 1.

2. I have reviewed the following references which are cited in this re-examination proceeding:

- Makuta et al, Application of Eicosapentaenoic Acid to Health Food, Japan Fudo Saiensu (1986), 25:1, 29-35 (Makuta)
- Gordeev et al., Chemistry of Natural Compounds (1990) 26(2) 143-147 (Gordeev)
- Kuroda et al., Comparison of Hypocholesterolemic Effect among Three Phospholipids Containing Different Fatty Acid and the Related Oils in Rats, Jap. J. Nutr. (1990), 48(5):213-20 (Kuroda)
- Canadian Application 2,251,265 (Beaudoin)
- WO 00/23546 (Sherbrooke)
- Japanese Laid Open Publication S63-23819 (Murata).


In this Declaration, I also refer to Fricke et al., Lipid, Sterol and Fatty Acid Composition of Antarctic Krill (*Euphausia superba* Dana)(1984) Lipids 19(11):821-827 (attached as Exhibit 2).

3. Krill are rich in a variety of liposoluble compounds including phospholipids, carotenoids such as astaxanthin, and vitamin E ( $\alpha$ -tocopherol). This fact is supported by Canadian Application 2,251,265 at p. 5 and WO 00/23546 at p. 9-11. Astaxanthin and  $\alpha$ -tocopherol are antioxidants. *Id.* The phospholipid fraction of krill contains phosphatidylcholine and phosphatidylethanolamine as well as other phospholipid species. See Fricke et al., p. 822, Table 1; See also WO 00/23546, p. 9-11 and Tables 14-18. A variety of fatty acids are attached to the phospholipids. These include docosahexaenoic acid, eicosahexaenoic acid, oleic acid, and linoleic acid among many others. WO 00/23546, p. 9-11 and Tables 14-18; Fricke et al., Tables 2-6.


4. Lipid extracts from krill have common characteristics. This is demonstrated by the fact that the different extraction protocols employed in WO 00/23546 (Tables 14-18), Fricke et al. (Tables 2-6), and Gordeev (Table 1) all produce lipid fractions containing phosphatidylcholine and phosphatidylethanolamine as well as other phospholipid species, docosahexaenoic acid, eicosahexaenoic acid, and oleic acid as well as many other fatty acids. The phospholipid fractions utilized by Kuroda (Tables 1 and 2) and described in Makuta (Tables 9 and 10) also contain these phospholipids and fatty acids. In each instance, liposoluble substances such as astaxanthin and  $\alpha$ -tocopherol would be present in the various krill lipid extracts and phospholipid fractions as demonstrated in WO 00/23546 at p. 9-11 and Tables 14-18. This means that the phospholipid fractions and krill lipid extracts in each of the references listed in Paragraph 2 above would contain phosphatidylcholine and phosphatidylethanolamine as well as other phospholipid species, docosahexaenoic acid, eicosahexaenoic acid, linoleic acid and oleic acid as well as many other fatty acids as listed in the various Tables, astaxanthin and  $\alpha$ -tocopherol. The phospholipid fractions and krill lipid extracts would also contain triglycerides and free fatty acids.

5. I further declare that all statement made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Dr. Nils Hoem



Date

# EXHIBIT 1

# Curriculum Vitae

Nils Ove Hoem, M.Sc.(Pharm), Ph. D.

## PROFESSIONAL BACKGROUND

---

|                           |  |   |
|---------------------------|--|---|
| Academic Appointments     | 1985-1989  | Research Assistant, Department of Pharmacology, School of Pharmacy, University of Oslo.   |
|                           | 1989-1990  | Assistant Professor, Department of Pharmacology, School of Pharmacy, University of Oslo.  |
|                           | 1990-1998  | Associate Professor, Department of Pharmacology, School of Pharmacy, University of Oslo.  |
|                           | 2000-2002  | Associate Professor, Department of Pharmacology, School of Pharmacy, University of Oslo   |
|                           | 2001-present   | Associated member of Laboratory of Applied Pharmacokinetics, USC, Los Angeles   |
| Non-Academic appointments | 1979-1980  | Teacher (Ellingsoy Junior High School)  |
|                           | 1984 - 2004  | Several shorter periods (1-4 weeks) as community Pharmacist in Norway   |
|                           | 1992-1996  | Project manager: Development and implementation of a Post Graduate one-year continuing education program for Pharmacists.                                   |
|                           | 1999   | Senior Regulatory Advisor, Smerud Medical Research Group, Oslo, Norway.   |
|                           | 2003   | Senior Scientific Consultant, Smerud Medical Research Group, Oslo, Norway.  |
|                           | 2003-2004  | Running own consultancy business. Hoem Pharma Consult in Oslo Norway. Consulting in Pharmacokinetics and in more general aspects of early drug development. |
|                           | 2004-2007  | Director PK/PD (Europe) MDS Pharma Services, Hamburg, Germany and Belfast Northern-Ireland  |
|                           | 2007-2007  | Director R&D Pronova Biocare AS, Lysaker, Norway  |
| 2008-2010                 | Vice President Research and Development Aker BioMarine, Norway |   |
| 2011-present              | Chief Scientist Aker BioMarine, Norway                         |   |

## LICENSURE

---

1983 - present Certified to Dispense Drugs in Norway.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.